E-submission
THE KOREAN LIVER CANCER ASSOCIATION
Search
- Page Path
- HOME > Search
Review Article
- A Review on Embolic Materials for Transcatheter Arterial Chemoembolization
- Byung Kook Kwak, Hyung Jin Shim
- Journal of the Korean Liver Cancer Study Group. 2011;11(1):1-5. Published online February 28, 2011
- 583 Views
- 5 Downloads
-
Abstract
PDF - Four procedures on intraarterial catheter-based therapy are available in treating hepatocellular carcinoma: intraarterial chemotherapy (IAC), transcatheter arterial embolization (TAE), conventional transcatheter arterial chemoembolization (cTACE), and transcatheter arterial chemoembolization using drug-eluting bead (DEB-TACE). On the bases of “2009 Practice Guideline for Diagnosis and Treatment of Hepatocellular Carcinoma” by The Korean Liver Cancer Study Group and National Cancer Center, and “2010 AASLD Practice Guideline” by American Association for the Study of Liver Disease, substances and recommendations on interventional managements were reviewed. Various kinds of embolic materials used in the procedures of TAE, cTACE and DEB-TACE were described in detail.
Case Report
- Two Cases of Hepatocellular Carcinoma with Extrahepatic Metastasis Who Showed Complete Remission Following Doxorubicin and Cisplatin (AP) Combination Chemotherapy in Reduced Dosage
- Seung Bum Nam, Chul Ju Han, Ho Jin Lee, Youn Joo Kim, Ki Young Yang, Su Cheol Park, Jin Kim, Yu Cheol Kim
- Journal of the Korean Liver Cancer Study Group. 2010;10(1):55-60. Published online June 30, 2010
- 633 Views
- 1 Download
-
Abstract
PDF
- The effect of systemic chemotherapy in patients with advanced HCC is very limited, not only in regard to poor response
to cytotoxic chemotherapeutic agents but also poor tolerance to therapy and related adverse effects. Herein, we report two
case
s of hepatocellular carcinoma (HCC) with extrahepatic metastasis who achieved complete remission following administration of doxorubicin and cisplatin in reduced dosage. The first case was a 41-year-old male who had HCC with multiple lung and intraabdominal lymph nodes metastasis. After 9 cycles of chemotherapy with 50% reduced dosage, he achieved a complete remission of both primary and metastatic lesions. He showed no evidence of disease for 11 more months during follow-up and still lives without recurrence. The second case was a 61-year-old female who had HCC with inferior vena cava thrombosis and multiple lung metastasis. After one cycle of treatment with 25% reduced dosage, she underwent life-threatening toxicities and poor tolerance to chemotherapy and further treatment was discontinued. However, she achieved a complete remission of both primary and metastatic lesions. Following 26 months of recurrence free period, she suffered from a recurrent tumor near previously treated lesion, which was successfully treated by TACE and radiation therapy. This modified doxorubicin and cisplatin regimen in reduced dosage could be used as means of evading life threatening toxicity and selecting out responders to systemic chemotherapy with reduced risk.
First
Prev
Follow JLC on Twitter